Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.
The Hairy Cell Leukemia pipeline drugs market research report outlays comprehensive information on the Hairy Cell Leukemia targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in Hairy Cell Leukemia targeted therapeutics development with respective active and dormant or discontinued projects.
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Targets
Some of the primary targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Targets
To know more about the targets in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Mechanisms of Action
The primary mechanisms of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Mechanisms of Action
To know more about the MoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Routes of Administration
To know more about the RoA in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Segmentation by Molecule Type
The key molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Molecule Type
To know more about the molecule type in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.
Hairy Cell Leukemia Pipeline Drugs Market Analysis, by Leading Companies
To know more about the leading companies in the Hairy Cell Leukemia pipeline drugs market, download a free report sample
Hairy Cell Leukemia Pipeline Drugs Market Report Overview
| Key Targets | Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3 |
| Key Mechanisms of Action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist |
| Key Routes of Administration | Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous |
| Key Molecule Types | Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein |
| Key Companies | F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Ascentage Pharma Group International
AstraZeneca Plc
Autolus Therapeutics Plc
Bristol-Myers Squibb Co
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
Incyte Corp
Jecho Biopharmaceuticals Co Ltd
MacroGenics Inc
Mediolanum farmaceutici SpA
Mustang Bio Inc
Novartis AG
Sorrento Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets in the Hairy Cell Leukemia pipeline drugs market?
Some of the targets in the Hairy Cell Leukemia pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf, Tyrosine Protein Kinase BTK, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, B Cell Lymphoma 2, and CD3.
-
What are the mechanisms of action in the Hairy Cell Leukemia pipeline drugs market?
The primary mechanism of action in the Hairy Cell Leukemia pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Serine/Threonine Protein Kinase B Raf Inhibitor, Tyrosine Protein Kinase BTK Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, B Cell Lymphoma 2 Inhibitor, and CD3 Agonist.
-
What are the routes of administration in the Hairy Cell Leukemia pipeline drugs market?
The routes of administration in the Hairy Cell Leukemia pipeline drugs market are Oral, Intravenous, Parenteral, Intralesional, and Subcutaneous.
-
What are the molecule types in the Hairy Cell Leukemia pipeline drugs market?
The molecule types in the Hairy Cell Leukemia pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Biologic, Monoclonal Antibody Conjugated, and Recombinant Protein.
-
Which are the leading companies in the Hairy Cell Leukemia pipeline drugs market?
Some of the leading companies in the Hairy Cell Leukemia pipeline drugs market are F. Hoffmann-La Roche Ltd, Incyte Corp, Wuhan Bio-Raid Biotechnology Co Ltd, AstraZeneca Plc, AbbVie Inc, Ascentage Pharma Group International, Autolus Therapeutics Plc, Bristol-Myers Squibb Co, Eureka Therapeutics Inc, and Jecho Biopharmaceuticals Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports